Share the post "Hester Biosciences ‘s Q3 2024-25 Latest News: Revenue Decreases by 5.62% Year-on-Year"
Highlights
🔹 The presented financial data is Consolidated to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company’s sales declined by -5.62 % over the year, decrease in net sales/revenue by -24.46 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 688.79 %. Marginal increase in other income during this quarter, up by 324.4%. 🔹 Profit over the Year and quarter: Significant improvement in profitability for Hester Biosciences Limited. Notable increase of 183.78 % in net profit Year to Year, Hester Biosciences Limited’s profitability increased by 35.96 % in this quarter. 🔹 EPS over the Year and quarter: EPS increased by 183.51 % Year to Year. EPS increased by 36 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 66.983 Cr | Rs. 83.692 Cr | Rs. 63.218 Cr | -24.46 % | -5.62 % |
| Expenses | Rs. 56.83 Cr | Rs. 64.53 Cr | Rs. 50.54 Cr | -21.68 % | -11.07 % |
| Operating Profit | Rs. 10.15 Cr | Rs. 19.16 Cr | Rs. 12.68 Cr | -33.82 % | + 24.93 % |
| OPM % | 15.15 % | 22.89 % | 20.06 % | -2.83 % | + 4.91 % |
| Other Income | Rs. 0.99 Cr | Rs. 1.84 Cr | Rs. 7.809 Cr | + 324.4 % | + 688.79 % |
| Interest | Rs. 2.19 Cr | Rs. 5.89 Cr | Rs. 3.81 Cr | -35.31 % | + 73.97 % |
| Depreciation | Rs. 3.75 Cr | Rs. 4.2 Cr | Rs. 4.29 Cr | + 2.14 % | + 14.4 % |
| Profit before tax | Rs. 5.2 Cr | Rs. 10.91 Cr | Rs. 12.39 Cr | + 13.57 % | + 138.27 % |
| Tax % | 45.95 % | 31.86 % | 15.8 % | -16.06 % | -30.15 % |
| Net Profit | Rs. 4.02 Cr | Rs. 8.39 Cr | Rs. 11.41 Cr | + 36 % | + 183.83 % |
| EPS in Rs | Rs. 4.73 | Rs. 9.86 | Rs. 13.41 | + 36 % | + 183.51 % |
Today, we’re looking at Hester Biosciences Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a significant year-over-year sales decline of -5.62 %. However, it did see a marginal slip of -24.46 % from the previous quarter. Expenses decreased slightly by -21.68 % quarter-on-quarter, aligning with the annual decline of -11.07 %. Operating profit, while up 24.93 % compared to last year, faced a quarter-on-quarter dip of -33.82 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 4.91 %, but a shrinkage of -2.83 % sequentially. Other income rose by 324.4 % compared to the last quarter, despite an annual growth of 688.79 %. Interest expenses dropped significantly by -35.31 % from the previous quarter, yet the year-over-year increase remains at a moderate 73.97 %. Depreciation costs climbed by 2.14 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 14.4 %. Profit before tax grew annually by 138.27 % but saw an increase from the preceding quarter by 13.57 %.
Tax expenses as a percentage of profits decreased slightly by -30.15 % compared to last year, with a more notable quarter-on-quarter decrease of -16.06 %. Net profit rose by 183.83 % year-on-year but experienced a 36 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 183.51 % but a quarterly rise of 36 %. In summary, Hester Biosciences Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 66.983 Cr | Rs. 83.692 Cr | Rs. 63.218 Cr | -24.46 % | -5.62 % |
| Expenses | Rs. 56.83 Cr | Rs. 64.53 Cr | Rs. 50.54 Cr | -21.68 % | -11.07 % |
| Operating Profit | Rs. 10.15 Cr | Rs. 19.16 Cr | Rs. 12.68 Cr | -33.82 % | + 24.93 % |
| Net Profit | Rs. 4.02 Cr | Rs. 8.39 Cr | Rs. 11.41 Cr | + 36 % | + 183.83 % |
| EPS in Rs | Rs. 4.73 | Rs. 9.86 | Rs. 13.41 | + 36 % | + 183.51 % |
In reviewing Hester Biosciences Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -5.62 % year-on-year, although there was a slight dip of -24.46 % from the previous quarter. Expenses decreased by -11.07 % compared to the previous year, with a decrease of -21.68 % quarter-on-quarter. Operating Profit surged by 24.93 % annually, and saw a -33.82 % decrease from the last quarter.
Net Profit showed yearly increase of 183.83 %, and experienced a 36 % increase from the previous quarter. Earnings Per Share (EPS) rose by 183.51 % annually, however rose by 36 % compared to the last quarter. In essence, while Hester Biosciences Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/IEX.png)